Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia technology to either enhance their products or ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...